Effectiveness and tolerability of nimotuzumab in unresectable, locally advanced/metastatic esophageal cancer: Indian hospital-based retrospective evidence
Context: Epidermal growth factor receptor (EGFR) is overly expressed in esophageal squamous cell carcinoma (ESCC) and is important prognostic and predictive biomarker. Nimotuzumab is a humanized anti-EGFR monoclonal antibody and has documented promising clinical outcomes and survival rates in variou...
Main Authors: | Sundaram Subramanian, Nithya Sridharan, V Balasundaram, Sameer Chaudhari |
---|---|
Format: | Article |
Language: | English |
Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2019-01-01
|
Series: | South Asian Journal of Cancer |
Subjects: | |
Online Access: | http://journal.sajc.org/article.asp?issn=2278-330X;year=2019;volume=8;issue=2;spage=112;epage=115;aulast=Subramanian |
Similar Items
-
Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: A hospital-based retrospective evidence
by: Sundaram Subramanian, et al.
Published: (2018-01-01) -
Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: An Indian rural hospital experience
by: Shyamji Rawat, et al.
Published: (2019-01-01) -
Nimotuzumab with intensity-modulated radiation therapy in unresectable and platinum-ineligible locally advanced head-and-neck cancer
by: K. Satish Srinivas, et al.
Published: (2020-01-01) -
High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy
by: Wang CY, et al.
Published: (2015-12-01) -
Efficacy and safety of concurrent chemoradiotherapy with or without Nimotuzumab in unresectable locally advanced squamous cell carcinoma of head and neck: Prospective comparative study - ESCORT-N study
by: Ashok Kumar, et al.
Published: (2019-01-01)